QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q3 Results and Advances Lead Candidate TPI 287 Toward Phase 2 GBM Study
CNS Pharmaceuticals (NASDAQ: CNSP) reported third-quarter 2025 results and highlighted continued progress with TPI 287, its blood-brain barrier–permeable abeotaxane in…